TY - JOUR
T1 - Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance
AU - Chen, Ying
AU - Lisok, Ala
AU - Chatterjee, Samit
AU - Wharram, Bryan
AU - Pullambhatla, Mrudula
AU - Wang, Yuchuan
AU - Sgouros, George
AU - Mease, Ronnie C.
AU - Pomper, Martin G.
N1 - Publisher Copyright:
© 2016 American Chemical Society.
PY - 2016/7/20
Y1 - 2016/7/20
N2 - Prostate-specific membrane antigen (PSMA) is overexpressed in the epithelium of prostate cancer and nonprostate solid tumor neovasculature. PSMA is increasingly utilized as a target for cancer imaging and therapy. Here, we report the synthesis and in vivo biodistribution of a low-molecular-weight PSMA-based imaging agent, 2-[3-(1-carboxy-5-{3-[1-(2-[18F]fluoroethyl)-1H-1,2,3-triazol-yl]propanamido}pentyl)ureido]pentanedioic acid ([18F]YC-88), containing an [18F]fluoroethyl triazole moiety. [18F]YC-88 was synthesized from 2-[18F]fluoroethyl azide and the corresponding alkyne precursor in two steps using either a one- or two-pot procedure. Biodistribution and positron emission tomography (PET) imaging were performed in immunocompromised mice using isogenic PSMA+ PC3 PIP and PSMA- PC3 flu xenografts. YC-88 exhibited high affinity for PSMA as evidenced by a Ki value of 12.9 nM. The non-decay corrected radiochemical yields of [18F]YC-88 averaged 14 ± 1% (n = 5). Specific radioactivities ranged from 320 to 2,460 Ci/mmol (12-91 GBq/μmol) with an average of 940 Ci/mmol (35 GBq/μmol, n = 5). In an immunocompromised mouse model, [18F]YC-88 clearly delineated PSMA+ PC3 PIP prostate tumor xenografts on imaging with PET. At 1 h postinjection, 47.58 ± 5.19% injected dose per gram of tissue (% ID/g) was evident within the PSMA+ PC3 PIP tumor, with a ratio of 170:1 of uptake within PSMA+ PC3 PIP to PSMA- PC3 flu tumor placed in the opposite flank. The tumor-to-kidney ratio at 2 h postinjection was 4:1. At or after 30 min postinjection, minimal nontarget tissue uptake of [18F]YC-88 was observed. Compared to [18F]DCFPyL, which is currently in clinical trials, the uptake of [18F]YC-88 within the kidney, liver, and spleen was significantly lower at all time-points studied. At 30 min and 1 h postinjection, salivary gland uptake of [18F]YC-88 was significantly less than that of [18F]DCFPyL. [18F]YC-88 is a new PSMA-targeted PET agent synthesized utilizing click chemistry that demonstrates high PSMA+ tumor uptake in a xenograft model. Because of its low uptake in the kidney, rapid clearance from nontarget organs, and relatively simple one-pot, two-step radiosynthesis, [18F]YC-88 is a viable new PET radiotracer for imaging PSMA-expressing lesions.
AB - Prostate-specific membrane antigen (PSMA) is overexpressed in the epithelium of prostate cancer and nonprostate solid tumor neovasculature. PSMA is increasingly utilized as a target for cancer imaging and therapy. Here, we report the synthesis and in vivo biodistribution of a low-molecular-weight PSMA-based imaging agent, 2-[3-(1-carboxy-5-{3-[1-(2-[18F]fluoroethyl)-1H-1,2,3-triazol-yl]propanamido}pentyl)ureido]pentanedioic acid ([18F]YC-88), containing an [18F]fluoroethyl triazole moiety. [18F]YC-88 was synthesized from 2-[18F]fluoroethyl azide and the corresponding alkyne precursor in two steps using either a one- or two-pot procedure. Biodistribution and positron emission tomography (PET) imaging were performed in immunocompromised mice using isogenic PSMA+ PC3 PIP and PSMA- PC3 flu xenografts. YC-88 exhibited high affinity for PSMA as evidenced by a Ki value of 12.9 nM. The non-decay corrected radiochemical yields of [18F]YC-88 averaged 14 ± 1% (n = 5). Specific radioactivities ranged from 320 to 2,460 Ci/mmol (12-91 GBq/μmol) with an average of 940 Ci/mmol (35 GBq/μmol, n = 5). In an immunocompromised mouse model, [18F]YC-88 clearly delineated PSMA+ PC3 PIP prostate tumor xenografts on imaging with PET. At 1 h postinjection, 47.58 ± 5.19% injected dose per gram of tissue (% ID/g) was evident within the PSMA+ PC3 PIP tumor, with a ratio of 170:1 of uptake within PSMA+ PC3 PIP to PSMA- PC3 flu tumor placed in the opposite flank. The tumor-to-kidney ratio at 2 h postinjection was 4:1. At or after 30 min postinjection, minimal nontarget tissue uptake of [18F]YC-88 was observed. Compared to [18F]DCFPyL, which is currently in clinical trials, the uptake of [18F]YC-88 within the kidney, liver, and spleen was significantly lower at all time-points studied. At 30 min and 1 h postinjection, salivary gland uptake of [18F]YC-88 was significantly less than that of [18F]DCFPyL. [18F]YC-88 is a new PSMA-targeted PET agent synthesized utilizing click chemistry that demonstrates high PSMA+ tumor uptake in a xenograft model. Because of its low uptake in the kidney, rapid clearance from nontarget organs, and relatively simple one-pot, two-step radiosynthesis, [18F]YC-88 is a viable new PET radiotracer for imaging PSMA-expressing lesions.
UR - http://www.scopus.com/inward/record.url?scp=84979620483&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84979620483&partnerID=8YFLogxK
U2 - 10.1021/acs.bioconjchem.6b00195
DO - 10.1021/acs.bioconjchem.6b00195
M3 - Article
C2 - 27270097
AN - SCOPUS:84979620483
SN - 1043-1802
VL - 27
SP - 1655
EP - 1662
JO - Bioconjugate Chemistry
JF - Bioconjugate Chemistry
IS - 7
ER -